Bonac Corporation
BiotechJapanClosed 2024
Total Raised
Undisclosed
Peak Valuation
Undisclosed
Employees
—
Year Collapsed
2024
Business model
RNA-based therapeutics research and drug development, including a COVID-19 treatment candidate.
In brief
Developed RNA-based drug candidates, including a COVID-19 treatment project that consumed significant research funds without delivering effective clinical results. Broader efforts to develop marketable pharmaceutical products also struggled to reach commercialization, and by 2023…
See the What Happened tab for the full account.
Key facts
- Founded
- 2003
- Closed
- 2024
- Headquarters
- Tokyo, Japan
- Industry
- Biotech
- Employees
- —
- Revenue
- Undisclosed
- Founders
- Kazutaka Nagashima
Related failures
Vedere Bio
2019–2023Biotech · USA
Ran out of funding$77M9 Meters Biopharma
2016–2023Biotech · USA
Ran out of fundingUndisclosedAcorda Therapeutics
1995–2024Biotech · USA
Ran out of fundingUndisclosedAthersys
1995–2024Biotech · USA
Ran out of fundingUndisclosedEiger BioPharmaceuticals
2008–2024Biotech · USA
Ran out of fundingUndisclosedHumanigen
1999–2024Biotech · USA
Ran out of fundingUndisclosed
Often compared with: Moderna, Alnylam Pharmaceuticals.